| Literature DB >> 32673568 |
Ayala Tovy1, Jaime M Reyes2, Michael C Gundry3, Lorenzo Brunetti4, Henry Lee-Six5, Mia Petljak5, Hyun Jung Park6, Anna G Guzman1, Carina Rosas1, Aaron R Jeffries7, Emma Baple7, Jonathan Mill7, Andrew H Crosby7, Valerie Sency8, Baozhong Xin8, Heather E Machado5, Danielle Castillo9, Jeffrey N Weitzel9, Wei Li6, Michael R Stratton5, Peter J Campbell5, Heng Wang8, Mathijs A Sanders10, Margaret A Goodell11.
Abstract
DNA methyltransferase 3A (DNMT3A) is the most commonly mutated gene in clonal hematopoiesis (CH). Somatic DNMT3A mutations arise in hematopoietic stem cells (HSCs) many years before malignancies develop, but difficulties in comparing their impact before malignancy with wild-type cells have limited the understanding of their contributions to transformation. To circumvent this limitation, we derived normal and DNMT3A mutant lymphoblastoid cell lines from a germline mosaic individual in whom these cells co-existed for nearly 6 decades. Mutant cells dominated the blood system, but not other tissues. Deep sequencing revealed similar mutational burdens and signatures in normal and mutant clones, while epigenetic profiling uncovered the focal erosion of DNA methylation at oncogenic regulatory regions in mutant clones. These regions overlapped with those sensitive to DNMT3A loss after DNMT3A ablation in HSCs and in leukemia samples. These results suggest that DNMT3A maintains a conserved DNA methylation pattern, the erosion of which provides a distinct competitive advantage to hematopoietic cells.Entities:
Keywords: DNMT3A; HSC; cell competition; clonal hematopoiesis; hematopoietic stem cells; mutation burden; mutation signature
Mesh:
Substances:
Year: 2020 PMID: 32673568 PMCID: PMC7494054 DOI: 10.1016/j.stem.2020.06.018
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633